🏛️ Verified NIH Record • Updated 2025-03-25
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease (NCT03019757)
🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Douglas Scharre
🩺 Plain-English Summary (8th-Grade Level)
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
Who can join: Review the eligibility criteria below.
Location: The Ohio State University — Columbus, Ohio
Age range: 18 Years
🧪 Interventions in This Study
- DaTscan (RADIATION)
- F18-AV-45 (RADIATION)
- FDG-PET (RADIATION)
- APOE genotype (GENETIC)
- Polysomnogram (PROCEDURE)
- Clinical Assessment (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- The Ohio State University — Columbus, Ohio
📞 Contact the Study Coordinator
Phone: (614) 293-6882
Email: jennifer.icenhour@osumc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer's Disease
- Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia — Calgary, Alberta
- A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology — Clermont, Florida
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease — Phoenix, Arizona
- DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease — Birmingham, Alabama
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Birmingham, Alabama
- A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Chandler, Arizona
Explore by condition: All Alzheimer's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.